{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["102"],"submitter":["Conte B"],"pubmed_abstract":["Background
Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a biological standpoint, immune infiltration plays a crucial role in TNBC prognosis. Currently, there is a lack of genomic tools aiding in treatment decisions for TNBC. This study aims to assess the effectiveness of a B-cell/immunoglobulin signature (IGG) alone, or in combination with tumor burden, in predicting prognosis and treatment response in patients with TNBC.Methods
Genomic and clinical data were retrieved from 7 cohorts: SCAN-B (N = 874), BrighTNess (n = 482), CALGB-40603 (n = 389), METABRIC (n = 267), TCGA (n = 118), GSE58812 (n = 107), GSE21653 (n = 67). IGG and a risk score integrating IGG with tumor/nodal staging (IGG-Clin) were assessed for event-free s"],"journal":["EBioMedicine"],"pagination":["105043"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10924177"],"repository":["biostudies-literature"],"pubmed_title":["A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies."],"pmcid":["PMC10924177"],"pubmed_authors":["Prat A","Martinez-Saez O","Parker JS","Falato C","Perou CM","Schettini F","Segui E","Garcia-Fructuoso I","Villacampa G","Staaf J","Vivancos A","Conte B","Lorman-Carbo N","Angelats L","Adamo B","Fratini B","Vidal Losada MJ","Hernandez AR","Sanfeliu E","Braso-Maristany F","Chic N","Gomez-Bravo R","Villagrasa P","Marin-Aguilera M","Pascual T","Pare L"],"additional_accession":[]},"is_claimable":false,"name":"A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.","description":"Background
Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a biological standpoint, immune infiltration plays a crucial role in TNBC prognosis. Currently, there is a lack of genomic tools aiding in treatment decisions for TNBC. This study aims to assess the effectiveness of a B-cell/immunoglobulin signature (IGG) alone, or in combination with tumor burden, in predicting prognosis and treatment response in patients with TNBC.Methods
Genomic and clinical data were retrieved from 7 cohorts: SCAN-B (N = 874), BrighTNess (n = 482), CALGB-40603 (n = 389), METABRIC (n = 267), TCGA (n = 118), GSE58812 (n = 107), GSE21653 (n = 67). IGG and a risk score integrating IGG with tumor/nodal staging (IGG-Clin) were assessed for event-free s","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-05-29T12:28:04.861Z","creation":"2024-11-09T19:15:58.109Z"},"accession":"S-EPMC10924177","cross_references":{"pubmed":["38447275"],"doi":["10.1016/j.ebiom.2024.105043"]}}